(Page creation)
 
Line 9: Line 9:
}}
}}


Nitric oxide is a naturally occurring endothelial-derived vasodilator that exhibits most of its vasodilatory effects in the pulmonary vasculature.<ref>{{Cite journal|last=Ichinose|first=Fumito|last2=Roberts|first2=Jesse D.|last3=Zapol|first3=Warren M.|date=2004-06-29|title=Inhaled Nitric Oxide|url=https://www.ahajournals.org/doi/10.1161/01.cir.0000134595.80170.62|journal=Circulation|volume=109|issue=25|pages=3106–3111|doi=10.1161/01.CIR.0000134595.80170.62}}</ref> It is frequently indicated for patients with right heart failure and hypoxemia. It exists as a colorless odorless gas, and is administered inhalationally.
Nitric oxide (NO) is a naturally occurring endothelial-derived vasodilator that exhibits most of its vasodilatory effects in the pulmonary vasculature.<ref>{{Cite journal|last=Ichinose|first=Fumito|last2=Roberts|first2=Jesse D.|last3=Zapol|first3=Warren M.|date=2004-06-29|title=Inhaled Nitric Oxide|url=https://www.ahajournals.org/doi/10.1161/01.cir.0000134595.80170.62|journal=Circulation|volume=109|issue=25|pages=3106–3111|doi=10.1161/01.CIR.0000134595.80170.62}}</ref> It is frequently indicated for patients with right heart failure and hypoxemia. It exists as a colorless odorless gas, and is administered inhalationally.


== Uses<!-- Describe uses of the drug. If appropriate, add subsections for each indication. --> ==
== Uses<!-- Describe uses of the drug. If appropriate, add subsections for each indication. --> ==
* Pulmonary HTN
** After heart transplant
* Right ventricular failure


== Contraindications<!-- List contraindications and precautions for use of the drug. --> ==
== Contraindications<!-- List contraindications and precautions for use of the drug. --> ==
Line 24: Line 28:


==== Mechanism of action<!-- Describe the mechanism of action for the primary uses of the drug. --> ====
==== Mechanism of action<!-- Describe the mechanism of action for the primary uses of the drug. --> ====
Nitric oxide diffuses to smooth muscle of pulmonary vasculature -> activates soluble guanylate cyclase (sGC) -> converts GTP to cGMP -> activates protein kinase G -> increases Ca2+ reuptake -> decreased calcium decreasing myosin phosphorylation -> relaxation of smooth muscle.


==== Adverse effects<!-- Describe any potential adverse effects of the drug. --> ====
==== Adverse effects<!-- Describe any potential adverse effects of the drug. --> ====
Line 32: Line 37:


== History<!-- Describe the historical development of the drug. --> ==
== History<!-- Describe the historical development of the drug. --> ==
Initially discovered in 1987. Won Nobel Prize in Physiology and Medicine in 1998.


== References ==
== References ==


[[Category:Drug reference]]
[[Category:Drug reference]]

Revision as of 18:33, 30 August 2021

Nitric oxide
Clinical data
Pharmacodynamics
Pharmacokinetics
Physical and chemical data
Article quality
Editor rating
Unrated
User likes
0

Nitric oxide (NO) is a naturally occurring endothelial-derived vasodilator that exhibits most of its vasodilatory effects in the pulmonary vasculature.[1] It is frequently indicated for patients with right heart failure and hypoxemia. It exists as a colorless odorless gas, and is administered inhalationally.

Uses

  • Pulmonary HTN
    • After heart transplant
  • Right ventricular failure

Contraindications

Absolute contraindications

Precautions

Pharmacology

Pharmacodynamics

Mechanism of action

Nitric oxide diffuses to smooth muscle of pulmonary vasculature -> activates soluble guanylate cyclase (sGC) -> converts GTP to cGMP -> activates protein kinase G -> increases Ca2+ reuptake -> decreased calcium decreasing myosin phosphorylation -> relaxation of smooth muscle.

Adverse effects

Pharmacokinetics

Chemistry and formulation

History

Initially discovered in 1987. Won Nobel Prize in Physiology and Medicine in 1998.

References

  1. Ichinose, Fumito; Roberts, Jesse D.; Zapol, Warren M. (2004-06-29). "Inhaled Nitric Oxide". Circulation. 109 (25): 3106–3111. doi:10.1161/01.CIR.0000134595.80170.62.